Genome BC Funds Precision Medicine Initiatives to Lower Costs

Genome British Columbia (Genome BC) is funding three projects designed to translate genetic insights into practical medical applications, according to reporting from the Financial Post.

Two of the initiatives focus on increasing accessibility and reducing the cost of personalized medicine. One project, led by Dr. Bruce Carleton of the University of British Columbia in partnership with Bob Mehr of Pure Integrative Pharmacies, is developing eight low-cost, off-the-shelf pharmacogenetic (PGx) test kits. While commercial PGx tests—which evaluate medication safety and efficacy based on a patient's genome—currently cost between $200 and $2,000, Dr. Carleton stated the goal is to offer kits for as low as $40. To support this rollout, pharmacists at 15 Pure Integrative Pharmacy locations in British Columbia will receive training on interpreting these tests.

A second project focuses on genetically informed nutrition planning to help patients manage chronic metabolic conditions, specifically targeting the reversal of type 2 diabetes by addressing individual insulin responses to macronutrients.

Additionally, a third project is developing testing to predict the most effective treatments for patients with aggressive blood cancers.

Sally Greenwood, Vice President of Public Affairs and Chief Operating Officer at Genome BC, stated that while research advancements are frequent, the true positive impact occurs when genomic technologies are made available to the patients who need them.